Stockreport

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- BOSTON--(BUSINESS WIRE)--Astria The [Read more]